3Fossella FV, DeVore R, Kerr RN, et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.J Clin Oncol, 2000.18(12): 2354-2362. 被引量：1
4Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-ceU lung cancer previously treated with platinum-based chemotherapy. Clin Oncol, 2000,18(10): 2095-2103. 被引量：1
5Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol, 2004, 22(9): 1589-1597. 被引量：1
6NSCLC Meta-Analyses Collaborative Group. Chemotherapyin addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controUed trials. J Clin Oncol, 2008, 26(28): 4617-4625. 被引量：1
7Carney DN. Lung cancer-time to move on from chemotherapy. New EnglJ Med, 2002, 346(2): 126-128. 被引量：1
8Jemal A, Siegel R, Ward E, et al. Cancer statistics. CA Cancer J Clin. 2009, 59(4): 225-249. 被引量：1
9Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell. 2000, 103(2): 211-225. 被引量：1
10Ciardiello F, Tortora G. EGFR antagonists in cancer treatment. New EnglJ Med, 2008, 358(11): 1160-1174. 被引量：1
